Hypothesis that explains and predicts expansion of ages of KD due to decreased IgG levels. by Hiromi Yamaguchi (2396248)

Subjects:

Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

Genetic progress for FFB (in percentage of hybrids performance at generation 0) in the La Mé population according to breeding scheme (RRS with 120 candidates, RRGS with 120 candida... by Billy Tchounke (16965084)

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Decreased production of antiviral factors in patients infected with SARS-CoV-2 due to reduced TLR7 expression by Julia Cataldo Lima (22811497)

“…</p> <p>The virus that causes coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a way of weakening the body’s early immune defense, called the innate immune system. …”

Comparison of detection results between YOLOv5s and P-YOLOv5s-GRNF. by Zhongjian Xie (4633099)

Subjects:

5-fluorouracil decreases rates of persistent and reappearing actinic keratoses: The VAKCC Trial by Moniyka Sachar (9399032)

Structure of YOLOv5s-SBC. by Zhongjian Xie (4633099)

Subjects:

Structure of P-YOLOv5s-GRNF. by Zhongjian Xie (4633099)

Subjects:

Comparative experiment of different YOLOv5 versions. by Zhongjian Xie (4633099)

Subjects:

HSP90 inhibition by RGRN-305 decreased the gene expression of proinflammatory cytokines induced by SARS-CoV-2 S protein. by Hakim Ben Abdallah (14578241)

Cronbach’s alpha and means the stigma of Suicide Scale Short Form (SOSS-SF). by Orrin D. Ware (14829115)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects: